LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. reduced its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 25.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 180,687 shares of the medical instruments supplier's stock after selling 60,418 shares during the period. Ameriprise Financial Inc. owned 0.80% of LeMaitre Vascular worth $16,649,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its stake in LeMaitre Vascular by 48.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock valued at $1,227,000 after acquiring an additional 4,330 shares in the last quarter. Invesco Ltd. increased its position in shares of LeMaitre Vascular by 50.5% during the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after purchasing an additional 58,720 shares in the last quarter. Barclays PLC lifted its holdings in shares of LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock valued at $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Compass Planning Associates Inc acquired a new stake in shares of LeMaitre Vascular in the 4th quarter worth $567,000. Finally, Teacher Retirement System of Texas grew its stake in LeMaitre Vascular by 31.8% during the 4th quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier's stock worth $9,385,000 after buying an additional 24,586 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Down 0.3%

Shares of LeMaitre Vascular stock traded down $0.24 on Thursday, reaching $81.26. 20,892 shares of the stock were exchanged, compared to its average volume of 165,194. The business has a 50 day moving average price of $84.38 and a two-hundred day moving average price of $92.77. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 44.32, a PEG ratio of 2.22 and a beta of 0.86. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The business had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business's quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.44 earnings per share. Research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.98%. LeMaitre Vascular's dividend payout ratio is presently 40.40%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on LMAT shares. Wells Fargo & Company started coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price target for the company. Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Lake Street Capital upped their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $98.14.

Insider Buying and Selling at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. The trade was a 26.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 18,733 shares of the firm's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $84.77, for a total value of $1,587,996.41. Following the sale, the chief executive officer now directly owns 1,873,651 shares in the company, valued at approximately $158,829,395.27. This trade represents a 0.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 102,009 shares of company stock valued at $8,721,836. 9.50% of the stock is owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.